Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting
نویسندگان
چکیده
منابع مشابه
Auto-antibodies in Patients with Inflammatory Bowel Disease Unclassified
Background: Inflammatory bowel disease unclassified (IBDU) is considered to be an aberrant immune response with loss of tolerance to many antigens. Objective: This paper tries to address whether there is any value to test for auto-antibodies in such patients. Methods: 60 patients with inflammatory bowel disease unclassified participated in the study. Auto-antibodies to nuclear antigen, intestin...
متن کاملClinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.
Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment of inflammatory bowel disease (IBD) following the good clinical responses reported by clinical trials for both Crohn’s disease and ulcerative colitis. However, the effects of VDZ on extraintestinal manifestations were not reported in these trials, and the ‘real life’ experience is still limited. On these p...
متن کاملSweet Syndrome Accompanying Inflammatory Bowel Disease in a Child
Acute neutrophilic dermatosis, first described in 1964 by Robert Douglas Sweet, is characterized by sudden onset fever, neutrophilic leukocytosis, and well demarcated erythematous papules, nodules, and plaques with dense neutrophilic infiltrates on histologic evaluation.Here is a report of a 7-year-old girl who presented with high grade fever, and discrete erythematous papular skin eruptions, w...
متن کاملDesigning biologic selectivity for inflammatory bowel disease – role of vedolizumab
Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate re...
متن کاملSystemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α₄β₇ integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn's disease, 3 ulcerative colitis) previously non-respondent to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scandinavian Journal of Gastroenterology
سال: 2021
ISSN: 0036-5521,1502-7708
DOI: 10.1080/00365521.2021.1938206